Universal HPLC detector offers near nanogram sensitivity

Published: 6-May-2010
Manufacturing Research & Development Analysis

NQAD is said to be a major advance in high-performance liquid chromatography detection

Dorton Analytical, a UK supplier of laboratory equipment, says its ultra-sensitive, universal Nano Quantity Analyte Detector (NQAD) is a major advance in high-performance liquid chromatography detection.

The NQAD is a different kind of aerosol-based detector for HPLC, the company says. Based on Condensation Nucleation (CNLSD) technology, the NQAD has the ability to detect sub-nanogram levels.

Benefiting from ultra-high sensitivity, the detector is suitable for searching for drug impurities, degradation products, excipients and when industrial hygiene is a concern. Both easy and hard-to-measure compounds can be quantified accurately with minimal sample preparation, the company says.

The NQAD detector also offers a wide dynamic range with superior linearity compared with other aerosol-based detectors. Chromophores and fluorophores are not needed for detection, thereby eliminating or decreasing the need for compound derivatisation. The detector is optimised for use in UHPLC, HPLC and SFC.

The company says it is easy to install and operate and therefore ideal for use in any laboratory.

See more

You may also like

Manufacturing

Setting standards for polymer and protein characterisation

Read more
SEC-3010 triple detector system uses GPC/SEC

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company
  4. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution

You may also like

Manufacturing

Setting standards for polymer and protein characterisation

SEC-3010 triple detector system uses GPC/SEC
Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025

As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Sustainability

UK Invests £9.9m to turn recycled nuclear material into lead-212 cancer therapies

A new UK-wide programme will use recycled nuclear fuel to create sustainable lead-212 targeted alpha therapies, aiming to deliver next-generation precision cancer treatments for hard-to-treat tumours
Research & Development

OSE Immunotherapeutics gets positive IDMC recommendation to continue Phase III trial of Tedopi for lung cancer

The Independent Data Monitoring Committee has endorsed the ongoing pivotal Phase III ARTEMIA study evaluating Tedopi in HLA-A2–positive metastatic non-small cell lung cancer
Subscribe now